Prostaglandin E1
SIGMA/P5515 - ≥98% (HPLC), synthetic
Synonym: (11α,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-enoic acid; Alprostadil; PGE1
CAS Number: 745-65-3
Empirical Formula (Hill Notation): C20H34O5
Molecular Weight: 354.48
EC Number: 212-017-2
MDL Number: MFCD00077860
Linear Formula: C20H34O5
Product Type: Chemical
This picture is provided solely for illustration purposes. Optical properties of the actual product may deviate. Relevant product information is printed on labeled products and other accompanying or available information material. This image depicts SKU: P5515-10MG
This picture is provided solely for illustration purposes. Optical properties of the actual product may deviate. Relevant product information is printed on labeled products and other accompanying or available information material. This image depicts SKU: P5515-1MG
This picture is provided solely for illustration purposes. Optical properties of the actual product may deviate. Relevant product information is printed on labeled products and other accompanying or available information material. This image depicts SKU: P5515-5MG
| assay | ≥98% (HPLC) |
| biological source | synthetic |
| form | (powder to crystals) |
| InChI | 1S/C20H34O5/c1-2-3-6-9-15 |
| InChI key | GMVPRGQOIOIIMI-DWKJAMRDSA |
| Quality Level | 200  |
| SMILES string | O=C1[C@H](CCCCCCC(O)=O)[C |
| solubility | ethanol: 5 mg/mL |
| storage temp. | −20°C |
| Application: | Prostaglandin E1 has been used: • as a platelet inhibitor to analyse its effect on autophagy • in platelet adhesion assay • to investigate its effect on cAMP production in thyroid glands of normal and growth-retarded mouse in vitro. |
| Biochem/physiol Actions: | Prostaglandin E1 (PGE1) is a hormone synthesized from dihomo-γ-linolenic acid (DGLA) by the action of enzyme prostaglandin synthase. It is a vasodilator and activates adenylate cyclase. It is majorly present in human semen and is a potent platelet aggregation inhibitor. PGE1 infusions is effective in treating limb ischemia and peripheral vascular disease. It is unstable and is hydrolyzed to PGA1 in the lungs. Nanoparticle encapsulation of PGE1 is essential for its delivery at the vascular injury site. It elicits vasodilator effects on the retinal artery and vein in central retinal artery occlusion (CRAO). PGE1 and its synthetic analog misoprostol interact with E-prostanoid receptor 4 (EP4) and elicits protection in chronic myelogenous leukemia (CML). |
| Symbol |  GHS06 |
| Signal word | Danger |
| Hazard statements | H301 |
| Precautionary statements | P301 + P310 + P330 |
| Hazard Codes | Xn |
| Risk Statements | 61-22 |
| RIDADR | UN 2811 6.1 / PGIII |
| WGK Germany | WGK 1 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | −20°C |
| UNSPSC | 12352211 |